Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia

Jennifer Chapman-Fredricks, Julia T. Geyer, Mahsa Khanlari, Adrienne Moul, Carmen Casas, Scot T. Connor, Yao-Shan Fan, Justin Watts, Ronan T Swords, Francisco Vega, Attilio Orazi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Monocytosis can develop during disease course in primary myelofibrosis simulating that seen in chronic myelomonocytic leukemia, and should not lead to disease reclassification. In contrast, at presentation, rare cases have clinical, morphologic, and molecular genetic features truly intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. The taxonomy and natural history of these diseases are unclear. We identified cases which either: (1) fulfilled the 2008 World Health Organization criteria for primary myelofibrosis but had absolute monocytosis and, when available, chronic myelomonocytic leukemia-related mutations (ASXL1, SRSF2, TET2) or (2) fulfilled criteria of chronic myelomonocytic leukemia but had megakaryocytic proliferation and atypia, marrow fibrosis, and myeloproliferative-type driver mutations (JAK2, MPL, CALR). Patients with established primary myelofibrosis who developed monocytosis and those with chronic myelomonocytic leukemia with marrow fibrosis were excluded. By combining the pathology databases of two large institutions, six eligible cases were identified. Patients were predominantly male and elderly with monocytosis at diagnosis (average 17.5%/2.3 × 10 3 /μl), organomegaly, primary myelofibrosis-like atypical megakaryocytes admixed with a variable number of chronic myelomonocytic leukemia-like hypolobated forms, variable myelodysplasia, marrow fibrosis and osteosclerosis. All had a normal karyotype and no myelodysplasia-associated cytogenetic abnormalities. Five of the patients in whom a more extensive molecular characterization was performed showed co-mutations involving JAK2 or MPL and ASXL1, SRSF2, TET2, NRAS, and/or KRAS. Disease progression has occurred in all and two have died. Rare patients present with features that overlap between primary myelofibrosis and chronic myelomonocytic leukemia and are thus difficult to classify based on current World Health Organization criteria. Biologically, these cases likely represent primary myelofibrosis with monocytosis, dysplasia, and secondary (non-driver) mutations at presentation. Alternatively, they may represent a true gray zone of neoplasms. Their clinical behavior appears aggressive and innovative therapeutic approaches may be beneficial in this particular subset.

Original languageEnglish (US)
Pages (from-to)429-441
Number of pages13
JournalModern Pathology
Volume31
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Leukemia, Myelomonocytic, Chronic
Primary Myelofibrosis
Neoplasms
Mutation
Fibrosis
Bone Marrow
Osteosclerosis
Megakaryocytes
Karyotype
Chromosome Aberrations
Disease Progression
Molecular Biology
Databases
Pathology

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. / Chapman-Fredricks, Jennifer; Geyer, Julia T.; Khanlari, Mahsa; Moul, Adrienne; Casas, Carmen; Connor, Scot T.; Fan, Yao-Shan; Watts, Justin; Swords, Ronan T; Vega, Francisco; Orazi, Attilio.

In: Modern Pathology, Vol. 31, No. 3, 01.03.2018, p. 429-441.

Research output: Contribution to journalArticle

Chapman-Fredricks, Jennifer ; Geyer, Julia T. ; Khanlari, Mahsa ; Moul, Adrienne ; Casas, Carmen ; Connor, Scot T. ; Fan, Yao-Shan ; Watts, Justin ; Swords, Ronan T ; Vega, Francisco ; Orazi, Attilio. / Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. In: Modern Pathology. 2018 ; Vol. 31, No. 3. pp. 429-441.
@article{2772bfcd3f1b4422b01d763a29f822db,
title = "Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia",
abstract = "Monocytosis can develop during disease course in primary myelofibrosis simulating that seen in chronic myelomonocytic leukemia, and should not lead to disease reclassification. In contrast, at presentation, rare cases have clinical, morphologic, and molecular genetic features truly intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. The taxonomy and natural history of these diseases are unclear. We identified cases which either: (1) fulfilled the 2008 World Health Organization criteria for primary myelofibrosis but had absolute monocytosis and, when available, chronic myelomonocytic leukemia-related mutations (ASXL1, SRSF2, TET2) or (2) fulfilled criteria of chronic myelomonocytic leukemia but had megakaryocytic proliferation and atypia, marrow fibrosis, and myeloproliferative-type driver mutations (JAK2, MPL, CALR). Patients with established primary myelofibrosis who developed monocytosis and those with chronic myelomonocytic leukemia with marrow fibrosis were excluded. By combining the pathology databases of two large institutions, six eligible cases were identified. Patients were predominantly male and elderly with monocytosis at diagnosis (average 17.5{\%}/2.3 × 10 3 /μl), organomegaly, primary myelofibrosis-like atypical megakaryocytes admixed with a variable number of chronic myelomonocytic leukemia-like hypolobated forms, variable myelodysplasia, marrow fibrosis and osteosclerosis. All had a normal karyotype and no myelodysplasia-associated cytogenetic abnormalities. Five of the patients in whom a more extensive molecular characterization was performed showed co-mutations involving JAK2 or MPL and ASXL1, SRSF2, TET2, NRAS, and/or KRAS. Disease progression has occurred in all and two have died. Rare patients present with features that overlap between primary myelofibrosis and chronic myelomonocytic leukemia and are thus difficult to classify based on current World Health Organization criteria. Biologically, these cases likely represent primary myelofibrosis with monocytosis, dysplasia, and secondary (non-driver) mutations at presentation. Alternatively, they may represent a true gray zone of neoplasms. Their clinical behavior appears aggressive and innovative therapeutic approaches may be beneficial in this particular subset.",
author = "Jennifer Chapman-Fredricks and Geyer, {Julia T.} and Mahsa Khanlari and Adrienne Moul and Carmen Casas and Connor, {Scot T.} and Yao-Shan Fan and Justin Watts and Swords, {Ronan T} and Francisco Vega and Attilio Orazi",
year = "2018",
month = "3",
day = "1",
doi = "10.1038/modpathol.2017.148",
language = "English (US)",
volume = "31",
pages = "429--441",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia

AU - Chapman-Fredricks, Jennifer

AU - Geyer, Julia T.

AU - Khanlari, Mahsa

AU - Moul, Adrienne

AU - Casas, Carmen

AU - Connor, Scot T.

AU - Fan, Yao-Shan

AU - Watts, Justin

AU - Swords, Ronan T

AU - Vega, Francisco

AU - Orazi, Attilio

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Monocytosis can develop during disease course in primary myelofibrosis simulating that seen in chronic myelomonocytic leukemia, and should not lead to disease reclassification. In contrast, at presentation, rare cases have clinical, morphologic, and molecular genetic features truly intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. The taxonomy and natural history of these diseases are unclear. We identified cases which either: (1) fulfilled the 2008 World Health Organization criteria for primary myelofibrosis but had absolute monocytosis and, when available, chronic myelomonocytic leukemia-related mutations (ASXL1, SRSF2, TET2) or (2) fulfilled criteria of chronic myelomonocytic leukemia but had megakaryocytic proliferation and atypia, marrow fibrosis, and myeloproliferative-type driver mutations (JAK2, MPL, CALR). Patients with established primary myelofibrosis who developed monocytosis and those with chronic myelomonocytic leukemia with marrow fibrosis were excluded. By combining the pathology databases of two large institutions, six eligible cases were identified. Patients were predominantly male and elderly with monocytosis at diagnosis (average 17.5%/2.3 × 10 3 /μl), organomegaly, primary myelofibrosis-like atypical megakaryocytes admixed with a variable number of chronic myelomonocytic leukemia-like hypolobated forms, variable myelodysplasia, marrow fibrosis and osteosclerosis. All had a normal karyotype and no myelodysplasia-associated cytogenetic abnormalities. Five of the patients in whom a more extensive molecular characterization was performed showed co-mutations involving JAK2 or MPL and ASXL1, SRSF2, TET2, NRAS, and/or KRAS. Disease progression has occurred in all and two have died. Rare patients present with features that overlap between primary myelofibrosis and chronic myelomonocytic leukemia and are thus difficult to classify based on current World Health Organization criteria. Biologically, these cases likely represent primary myelofibrosis with monocytosis, dysplasia, and secondary (non-driver) mutations at presentation. Alternatively, they may represent a true gray zone of neoplasms. Their clinical behavior appears aggressive and innovative therapeutic approaches may be beneficial in this particular subset.

AB - Monocytosis can develop during disease course in primary myelofibrosis simulating that seen in chronic myelomonocytic leukemia, and should not lead to disease reclassification. In contrast, at presentation, rare cases have clinical, morphologic, and molecular genetic features truly intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. The taxonomy and natural history of these diseases are unclear. We identified cases which either: (1) fulfilled the 2008 World Health Organization criteria for primary myelofibrosis but had absolute monocytosis and, when available, chronic myelomonocytic leukemia-related mutations (ASXL1, SRSF2, TET2) or (2) fulfilled criteria of chronic myelomonocytic leukemia but had megakaryocytic proliferation and atypia, marrow fibrosis, and myeloproliferative-type driver mutations (JAK2, MPL, CALR). Patients with established primary myelofibrosis who developed monocytosis and those with chronic myelomonocytic leukemia with marrow fibrosis were excluded. By combining the pathology databases of two large institutions, six eligible cases were identified. Patients were predominantly male and elderly with monocytosis at diagnosis (average 17.5%/2.3 × 10 3 /μl), organomegaly, primary myelofibrosis-like atypical megakaryocytes admixed with a variable number of chronic myelomonocytic leukemia-like hypolobated forms, variable myelodysplasia, marrow fibrosis and osteosclerosis. All had a normal karyotype and no myelodysplasia-associated cytogenetic abnormalities. Five of the patients in whom a more extensive molecular characterization was performed showed co-mutations involving JAK2 or MPL and ASXL1, SRSF2, TET2, NRAS, and/or KRAS. Disease progression has occurred in all and two have died. Rare patients present with features that overlap between primary myelofibrosis and chronic myelomonocytic leukemia and are thus difficult to classify based on current World Health Organization criteria. Biologically, these cases likely represent primary myelofibrosis with monocytosis, dysplasia, and secondary (non-driver) mutations at presentation. Alternatively, they may represent a true gray zone of neoplasms. Their clinical behavior appears aggressive and innovative therapeutic approaches may be beneficial in this particular subset.

UR - http://www.scopus.com/inward/record.url?scp=85043388031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043388031&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2017.148

DO - 10.1038/modpathol.2017.148

M3 - Article

C2 - 29192651

AN - SCOPUS:85043388031

VL - 31

SP - 429

EP - 441

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 3

ER -